05/24/23 7:10 AMNasdaq : KMDA earningsKamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability GuidanceTotal Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-Year First Quarter 2023 EBITDA of $3.8 Million, Increase of 16% Year-over-Year Solid First Quarter Results and Expected Continued Momentum Supported by Multiple Growth Drivers Anticipated to Drive Full-Year 2023 EBITDARHEA-AIneutral
05/24/23 7:05 AMNasdaq : KMDA managementKamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate SecretaryKamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in theRHEA-AIneutral
05/24/23 7:00 AMNasdaq : KMDA Kamada Announces $60 Million Private Placement with FIMI Opportunity FundsKamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical companyRHEA-AIneutral
05/17/23 7:00 AMNasdaq : KMDA earningsKamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, todayRHEA-AIneutral
05/16/23 7:00 AMNasdaq : KMDA Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in SwitzerlandSwitzerland is the first European country to approve Glassia ®, which received U.S. FDA approval in 2010 Glassia will be commercialized by IDEOGEN AG in Switzerland and the therapy is expected to be available to patients and providers during the second half of 2023 The current Alpha-1 AntitrypsinRHEA-AIneutral
05/03/23 7:00 AMNasdaq : KMDA fda approvalKamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in IsraelSales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021 with Approximately $23 Million in Revenues in 2022 , and Gross Margins Over 50% Approval to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency REHOVOT, Israel and HOBOKEN, N.J.,RHEA-AIvery positive
03/15/23 7:10 AMNasdaq : KMDA Kamada Issues 2023 CEO Letter to ShareholdersKamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field,RHEA-AIvery positive
03/15/23 7:00 AMNasdaq : KMDA earningsKamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability GrowthTotal Revenues for Fiscal Year 2022 of $129.3 Million Represent ed Growth of 25% Compared to Fiscal Year 2021 ; Fourth Quarter 2022 Revenues of $45. 4 Million Represent ed a 44% Increase Year - over - Year Fiscal Year 2022 EBITDA of $1 7.8 million, Represent ed Margins of 14%, and a 3x IncreaseRHEA-AIpositive
03/09/23 8:00 AMNasdaq : KMDA earningsKamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, todayRHEA-AIneutral
01/04/23 7:00 AMNasdaq : KMDA Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in IsraelFDA Approval Currently Expected by Mid-2023 Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50% Ability to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency REHOVOT, Israel and HOBOKEN, N.J. , Jan.RHEA-AIvery positive